FY2025 EPS Estimate for Celldex Therapeutics Cut by Analyst

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Celldex Therapeutics in a research note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will earn ($3.67) per share for the year, down from their prior estimate of ($3.61). Cantor Fitzgerald currently has a “Overweight” rating and a $67.00 target price on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The firm had revenue of $1.18 million during the quarter, compared to the consensus estimate of $1.25 million.

Several other analysts have also recently commented on CLDX. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Friday, February 28th. The Goldman Sachs Group reduced their price objective on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a research report on Monday. Finally, UBS Group began coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They set a “buy” rating and a $44.00 target price on the stock. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $55.38.

Celldex Therapeutics Price Performance

Celldex Therapeutics stock opened at $21.10 on Thursday. The business has a 50 day simple moving average of $23.56 and a 200-day simple moving average of $28.64. Celldex Therapeutics has a 12 month low of $18.61 and a 12 month high of $50.73. The stock has a market capitalization of $1.40 billion, a PE ratio of -8.21 and a beta of 1.76.

Hedge Funds Weigh In On Celldex Therapeutics

Several hedge funds have recently bought and sold shares of CLDX. Deep Track Capital LP acquired a new stake in Celldex Therapeutics in the fourth quarter valued at $38,919,000. Wellington Management Group LLP grew its stake in Celldex Therapeutics by 14.5% in the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock valued at $314,190,000 after acquiring an additional 1,167,659 shares during the last quarter. Point72 Asset Management L.P. grew its stake in Celldex Therapeutics by 50.8% in the 4th quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company’s stock valued at $63,579,000 after acquiring an additional 847,264 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Celldex Therapeutics by 23.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company’s stock worth $89,890,000 after acquiring an additional 676,771 shares during the last quarter. Finally, Jennison Associates LLC raised its position in Celldex Therapeutics by 32.0% during the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock worth $45,017,000 after acquiring an additional 321,325 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.